Inhibin B/FSH Ratio as a Predictor of Testicular Pathology in NOA
Key facts
- Who runs it
- Elazıg Fethi Sekin Sehir Hastanesi
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 73 people enrolled
- Started
- 10 Jan 2026
- Ended
- 5 Feb 2026
- Type of study
- Observational, 5 groups
- Record updated
- 17 February 2026
Who can take part
- Age
- 18 years and older
- Sex
- Men only
- Healthy volunteers
- Cannot take part
Show the full registry criteria (6)Hide the full registry criteria
Who can take part
- Male patients who underwent micro-TESE for non-obstructive azoospermia
- Available histopathological evaluation of testicular tissue
- Available preoperative serum hormone measurements (FSH, LH, testosterone, Inhibin B)
Who cannot take part
- Previous testicular malignancy
- History of chemotherapy or radiotherapy affecting spermatogenesis
- Incomplete clinical, hormonal, or histopathological data
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This retrospective observational study evaluated the diagnostic and predictive value of serum Inhibin B (INHB), follicle-stimulating hormone (FSH), and the INHB/FSH ratio in differentiating histopathological subtypes of non-obstructive azoospermia (NOA) in men undergoing microdissection testicular sperm extraction (micro-TESE). Seventy-three patients treated at a single tertiary referral center between January 2023 and September 2025 were included. Hormonal parameters were assessed preoperatively, and histopathological findings were categorized into five groups (SCOS, EMA, LMA, HSG, NS). The INHB/FSH ratio demonstrated significant discriminative ability across histopathological patterns and showed strong predictive performance in ROC and regression analyses. These findings suggest that the INHB/FSH ratio may serve as a practical, non-invasive biomarker for estimating testicular pathology severity in NOA patients.
The 5 groups in the trial
- Early Maturation Arrest (EMA)
Patients diagnosed with early maturation arrest based on testicular histopathological evaluation.
- Late Maturation Arrest (LMA)
Patients diagnosed with late maturation arrest according to histopathological findings.
- Hypospermatogenesis (HS)
Patients with histopathologically confirmed hypospermatogenesis.
- Normospermatogenesis (NS)
Patients with normal spermatogenesis on histopathological examination.
- Sertoli Cell-Only Syndrome (SCOS)
Patients diagnosed with Sertoli cell-only syndrome based on testicular biopsy findings.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Predictive Value of Serum Inhibin B/FSH Ratio in Estimating Pathology Results in Patients Undergoing Micro-TESE Due to Azoospermia
- Record updated
- 17 February 2026